extracellular vesicles from human adipose tissue-derived mesenchymal stem cells

Extracellular vesicles from human adipose tissue-derived mesenchymal stem cells (hAT-MSCs) are nano-sized, membrane-bound vesicles (including exosomes and microvesicles) secreted by hAT-MSCs. These vesicles carry cargoes such as proteins, lipids, and nucleic acids (mRNA, microRNA, long non-coding RNA, DNA), closely reflecting the bioactive profile of their parent MSCs[1][2][3]. hAT-MSC-EVs exert therapeutic effects primarily through intercellular communication by delivering their cargo to recipient cells, modulating immune responses, enhancing tissue repair, and promoting angiogenesis, anti-inflammation, and anti-apoptosis. They have shown preclinical benefit in models of inflammatory, neurodegenerative, hepatic, cardiac, and skin diseases, often matching or exceeding the effect of the parent MSCs[2][3]. Compared to cell therapy, EVs have reduced risks of tumorigenicity, immune rejection, and embolism, as well as improved safety and the ability to cross biological barriers such as the blood-brain barrier[1][2]. They are being investigated as cell-free therapies and advanced drug delivery vehicles, with potential for biological or chemical engineering to enhance targeting or therapeutic payload[1][3]. Clinical translation requires stringent process control, characterization, manufacturing, and safety assessment[1][3].

Other names

extracellular vesicles from hAT-MSCshAT-MSC-EVsMSC-EVs from hATexosomes from hAT-MSCshuman adipose tissue mesenchymal stem cell extracellular vesicles